Tag: Drug Patents

U.S. District Court Rules in Favor of Sanofi and Regeneron in Praluent® Patent Litigation

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for...

US District Court Upheld Validity of Two Patents Covering Amgen’s Enbrel

A US district court upheld the validity of two patents covering Amgen's Enbrel (etanercept) in response to a lawsuit the company filed against Novartis' Sandoz unit over the latter's biosimilar Erelzi...

Akebia Therapeutics® Settled Patent Ligitation with Par Pharmaceutical

Akebia Therapeutics, Inc. announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and License Agreeme...

New Turn in Patent Dispute Between Bristol-Myers Squibb and Natco Pharma

A patent dispute between USA-based pharma major Bristol-Myers Squibb and Indian pharma company Natco Pharma has taken a new turn with the Delhi High Court awarding interim relief to Hyderabad-based Na...

Current Status of IPR Protection in Russian Pharmaceutical Sector

This video briefly looks at the current status of intellectual property rights protection in Russia’s pharmaceutical sector. This video covers 3 basic topics: compulsory licensing, taking into...

US Court to Hear Aurobindo Pharma over Patent Infringement Allegations

Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg...

AbbVie and Boehringer Ingelheim Resolve HUMIRA® U.S. Patent Litigation

AbbVie announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant Boehringer Ingelheim a non-exclusive lice...

Vectura Won Patent Case Against GlaxoSmithKline

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages fo...

Merck’s 13th CRISPR Patent

Merck, a leading science and technology company and leader in genome editing, announced that the Canadian Patent Office has allowed Merck’s patent application directed to the use of paired CRISPR nick...

Sanofi and Regeneron Disagree Amgen to Keep Patents

Sanofi and Regeneron Pharmaceuticals Inc. announced they strongly disagree with certain aspects of jury verdict from the U.S. District Court for the District of Delaware. The jury upheld the validity ...

Amgen Keeps Patents Related to PCSK9 antibodies

Amgen announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amg...

US Patent for Oral Mucositis Drug

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office issued a new patent to the Company for the treatment of oral mu...

The European Union’s General Court reduces cartel fine on Servier

The European Union’s General Court has reduced an EU fine on the French pharmaceutical company Servier

Russia prepares legislation changes to combat ‘ever greening’ patents

Rospatent published a document on amendments to the Rules for drawing up, filing and reviewing documents for committing legally significant actions for the state registration of inventions.

Rospatent invalidated the patent for tadalafil 1-20 mg

The Russian Federal Service for Intellectual Property (Rospatent) invalidated the Eurasian patent No. 005416 for the group of inventions "Unified Dosage Form" issued to Eli Lilly.

Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.